Indomethacin Capsule 25mg Bp Uap

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Still deciding? Get samples of US$ 0/Piece
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Indomethacin Capsule 25mg Bp Uap
  • Indomethacin Capsule 25mg Bp Uap
  • Indomethacin Capsule 25mg Bp Uap
  • Indomethacin Capsule 25mg Bp Uap
  • Indomethacin Capsule 25mg Bp Uap
  • Indomethacin Capsule 25mg Bp Uap
Find Similar Products

Basic Info.

Model NO.
AMC11007-01
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Capsules
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Transport Package
25mg, 10X10caps/Box
Specification
Indomethacin BP98 25mg
Trademark
Medipharm, OEM
Origin
China
HS Code
3004909099
Production Capacity
10000ctns Per Month

Product Description

Indications:
The treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute musculoskeletal disorders and acute gout.
Contra-indications: 
Active peptic ulcer or a history of recurrent gastro-intestinal lesions. Sensitivity to aspirin, indometacin or other non-steroidal anti-inflammatory agents. 
Pregnancy or lactation. 
Patients operating machinery. 
Patients with epilepsy, parkinsonism, psychiatric disturbances or porphyria. 
Children, since conditions for safe use have not been established. 
Severe heart failure.
Indomethacin Capsule 25mg Bp Uap
Adverse Effects:
Most adverse effects are dose related 
Gastro-intestinal adverse effects are common and include anorexia, nausea (with or without vomiting) dyspepsia, abdominal pain and diarrhoea. Infrequently, ulceration of the upper GI tract, sometimes with perforation and haemorrhage, has occurred. Acute pancreatitis has been reported. Hepatic involvement is rare, though fatal cases of hepatitis and jaundice have been reported. 
CNS effects are also common. Severe frontal headache may occur in 25 - 50% of patients who take the drug chronically. Dizziness, light-headedness, vertigo and mental confusion are also frequent. Depression and psychosis have also been reported but the incidence is less than 1%. 
Haemopoietic reactions, including neutropenia, thrombocytopenia and, rarely, aplastic anaemia have been reported. 
Hypersensitivity reactions, manifested as rashes, itching, urticaria or rarely acute asthma, may occur. 
Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.

Drug Interactions:
1. The plasma concentration of Indometacin is increased. 
2. Frusemide. The natriuretic and anti-hypersensitivity effects are antagonised by Indometacin. 
3. Thiazide diuretics and beta-blocking agents. Indometacin reduces the anti-hypertensive effects of these compounds. 
4. Antacids. The bioavailability of Indometacin may be reduced by concomitant antacid therapy. 
5. Acute renal failure has been reported with concomitant Indometacin therapy.

Precautions & Warning:
Indometacin should be used with great care in elderly patients. Indometacin should be used with caution in patients with impaired renal function. Indometacin inhibits platelet aggregation and prolongs bleeding time. It should be used with caution therefore in patients with bleeding disorders, and concurrent administration of anti-coagulant agent may be hazardous because of increased risk of gastrointestinal bleeding
Peptic ulcer has been reported in a small proportion of patients. If G.I. bleeding occurs, indometacin should be discontinued immediately. Indometacin may mask the signs and symptoms of infection. If clinical signs of hepatic disease develop, or if liver function tests become abnormal, indometacin should be withdrawn. Indometacin should be given with or immediately after food in order to lessen the incidence and severity of gastrointestinal side-effects. 
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below).

Use in Pregnancy and Nursing Mothers:
Indometacin is contraindicated during pregnancy and lactation.

Treatment/antidote in The Event of Overdose:
Gastric lavage should be performed if ingestion is recent. Otherwise, supportive measures and observation.

Storage instructions:
Store below 25ºC. Protect from moisture. Keep out of reach of children.

Production:
Indomethacin Capsule 25mg Bp Uap  
Inspection:
Indomethacin Capsule 25mg Bp Uap
Loading:
Indomethacin Capsule 25mg Bp Uap
Certificates:
Indomethacin Capsule 25mg Bp Uap

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier